Several small molecule inhibitors were designed to disrupt the MLL1‐WDR5 interaction as a novel therapeutic strategy to treat leukemia caused by MLL1 hyperactivity (Cao et al., 2014; Karatas et al., 2013; Li et al., 2016). Here, KMT2A is linked to leukemia.